NCCN 2026 Nursing Program: Advancing Oncology Nursing™

March 26, 2026

The NCCN 2026 Nursing Program: Advancing Oncology Nursing™ addresses the expanding role of nurses in areas such as early-phase clinical trial participation, therapeutic administration, radiation guidance, and perioperative care. The program also explores strategies for addressing social determinants of health, enhancing symptom management, and facilitating difficult patient conversations with compassion and confidence.

By engaging in case-based learning and expert-led discussions, learners will strengthen their clinical decision-making and patient advocacy skills, ultimately improving outcomes and quality of life for people with cancer. 

Target Audience

This program is designed to meet the educational needs of oncology nurses who treat people with cancer.

Learning Objectives

Following this program, participants should be able to:

Overall Learning Objectives
  • Discuss advances in the treatment of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology and apply appropriate treatment and supportive care strategies to optimize patient education and care.
  • Assess and address the physical, emotional, and social needs of patients with cancer through comprehensive symptom management, psychosocial screening, and survivorship planning.
  • Demonstrate effective communication, clinical judgement, and interdisciplinary collaboration to enhance nursing practice and patient safety in the cancer care environment. 
The Experience of Early Phase Clinical Trial Participants
  • Explain the purpose, design, and therapeutic focus of early-phase clinical trials, including recent advances in efficacy and safety. 
  • Assess the challenges experienced by people with cancer participating in early-phase trials, particularly those with advanced disease and limited standard-of-care options. 
  • Integrate principles of early palliative and supportive care into nursing practice to optimize quality of life, facilitate access to novel therapies, and enhance the overall clinical trial experience for people with cancer. 
Screening for More than Cancer: Social Determinants of Health Assessments in the Infusion Suite Using the NCCN Distress Thermometer
  • Define health equity and its relationship to social determinants of health (SDOH) in oncology. 
  • Identify key factors within SDOH that can impact cancer treatment outcomes and patient well-being. 
  • Explain the benefits and applications of the NCCN Distress Thermometer for addressing both distress and SDOH in the infusion suite. 
Gastric and Esophageal Cancers: Clinical Updates and Nursing Implications
  • Identify emerging therapies for patients with either esophageal or gastric cancer. 
  • Identify nursing interventions in the care of patients receiving newer immunotherapies and targeted therapies.  
  • Understand the impact the nursing role will have on quality of life and patient outcomes in this setting. 
Radiating Care: The Nurse's Role in Guiding Patients Through Radiation for Head and Neck Cancers
  • Discuss the radiation treatment modalities used in head and neck cancers.    
  • Review the most common side effects associated with radiation therapy in head and neck cancers. 
  • Apply nursing interventions to best support patients receiving radiation therapy for head and neck cancers. 
The Role of Accurate Antineoplastic Drug Administration in Optimizing Patient-Centered Cancer Care
  • Understand the critical importance of accurate drug administration in the oncology setting and become familiarized with the most up-to-date best practices. 
  • Identify different routes and techniques of administration of antineoplastic drugs as newer therapies are becoming available. 
  • Recognize the obstacles that oncology nurses face when trying to administer full doses of small drug volumes and learn ways to work with the interprofessional team to improve the drug delivery process that enhances patient and nurse safety, improves patient wait times, and prevents suboptimal dosing. 
An Oncology-Specific Outpatient Perioperative Department: What an Extended Recovery Unit Can Offer Post Surgery
  • Describe the Extended Recovery Unit (ERU) model. 
  • Identify specialized training required for oncology nurses working in ERUs. 
  • Discuss the impact of ERUs on patient outcomes, hospital bed shortages and post-operative workflows. 
Difficult Discussions in Oncology Nursing: Tools, Techniques and Compassion
  • Identify barriers to therapeutic communication. 
  • Recognize and respond to a wide range of emotions fostered by the patient and their caregivers. 
  • Incorporate communication models and strategies to navigate challenging interactions. 
Additional information
Supporters: 

This activity is supported by educational grants from: 

  • AstraZeneca
  • Ipsen Biopharmaceuticals, Inc.
  • Novartis

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Supported by a grant from Pfizer Inc.

This educational activity is supported by an independent medical education grant from GSK. 

Course summary
Available credit: 
  • 5.25 ANCC contact hours
    • 1.50 ANCC Pharmacology Contact Hours
  • 5.25 Participation
Course opens: 
03/26/2026
Course expires: 
06/30/2026
Event starts: 
03/26/2026 - 8:00am EDT
Event ends: 
03/26/2026 - 3:00pm EDT

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Lorena Delgado, RN, MSN, OCN
Megan Hunter, BSN, RN, CCRN
Rochelle Jackson, DNP, APRN, FNP-C
Justin T. Kelly, MHI, BSN, RN, CCRN, RHIA, CL IV
Deborah Lundquist, PhD, RN
Molly Nestor, MSN, FNP-C, AOCNP
Heather O’Neal, MHI, BSN, RN, OCN
Carey Ramirez, DNP, ANP-C, ACHPN
Johanna Rochat, BSN, RN, OCN
Amanda E. Visnick, RN, BSN, OCN

The faculty listed below has the following relevant financial relationship with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated. 

MiKaela Olsen, DNP, APRN-CNS, AOCNS, FAAN
BD: Consulting Fee; Honoraria

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image
Joint Accreditation
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 5.25 contact hours. This program offers 1.5 pharmacotherapeutic contact hours for nurses. Eligible sessions are: 

  • Gastric and Esophageal Cancers: Clinical Updates and Nursing Implications
  • The Role of Accurate Antineoplastic Drug Administration in Optimizing Patient-Centered Cancer Care 

Available Credit

  • 5.25 ANCC contact hours
    • 1.50 ANCC Pharmacology Contact Hours
  • 5.25 Participation
Please login or register to take this course.

Click the Take Course button to take the pre-test.

You must be logged in with the same email address used for program registration.

Check your email for instructions on how to access the virtual event platform for session handouts and live streaming. Check your spam folder if you do not see the message in your inbox.

Contact [email protected] if you need assistance. 

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing